Altered Bile Acid Metabolism during Treatment with Phenobarbitone

1973 ◽  
Vol 45 (2) ◽  
pp. 257-262 ◽  
Author(s):  
N. E. Miller ◽  
P. J. Nestel
Keyword(s):  
Bile Acid ◽  
Acid Metabolism ◽  
Plasma Cholesterol ◽  
Low Density Lipoprotein ◽  
Specific Radioactivity ◽  
Density Lipoprotein ◽  
Bile Acid Metabolism ◽  
Faecal Excretion ◽  
Healthy Humans ◽  
Early Rise

1. The effects of phenobarbitone on cholesterol and bile acid metabolism have been examined in healthy humans. 2. In three of four subjects the faecal excretion of bile acids was increased by phenobarbitone. This was associated with an increased pool size and turnover of cholic acid. Cholesterol excretion was not clearly affected. The fourth subject who did not respond was also exceptional in not showing an increase in the plasma clearance of antipyrine. 3. The three responsive subjects also developed significant increases in plasma cholesterol and triglyceride concentrations. These findings were associated with an early rise in very-low-density lipoprotein and a fall in plasma cholesterol specific radioactivity in one patient, changes compatible with increased cholesterol synthesis.

Changes in Plasma Lipoprotein Lipids in Hypercholesterolaemic Patients Treated with the Bile Acid-Sequestering Resin, Colestipol

1974 ◽  
Vol 47 (6) ◽  
pp. 547-557 ◽  
Author(s):  
P. Clifton-Bligh ◽  
N. E. Miller ◽  
P. J. Nestel
Keyword(s):  
Bile Acid ◽  
Plasma Concentration ◽  
Plasma Cholesterol ◽  
Low Density Lipoprotein ◽  
Specific Radioactivity ◽  
Early Period ◽  
Density Lipoprotein ◽  
Plasma Lipoproteins ◽  
Low Density ◽  
The Individual

1. Seven patients with type II hyperlipoproteinaemia were treated with the bile acid-sequestering resin, colestipol (5 g three times daily), after a prolonged period of taking placebo. 2. After 8–9 weeks of treatment, the plasma concentration of the non-esterified cholesterol of very-low-density lipoprotein (VLDL) had risen by a mean of 0.09 mmol/l (43% increase, P < 0.001), that of the esterified cholesterol of VLDL had risen by a mean of 0.11 mmol/l (38% increase, P < 0.01), and that of the triglyceride of VLDL had risen by a mean of 0.40 mmol/l (53% increase, P<0.001). During the same period, the plasma concentration of the non-esterified cholesterol of low-density lipoprotein (LDL) decreased by a mean of 0.44 mmol/l (26% decrease, P < 0.01), that of the esterified cholesterol of LDL decreased by a mean of 1.28 mmol/l (30% decrease, P< 0.001), and that of the triglyceride of LDL decreased by a mean of 0.04 mmol/l (8% decrease, P < 0.01). No significant changes occurred in the plasma concentration of either the cholesterol or triglyceride of high-density lipoprotein (HDL) during treatment. 3. During the early period of treatment with colestipol, changes took place in the specific radioactivity of plasma cholesterol (labelled by intravenous injection of [3H]cholesterol), which, together with the changes in the mass of cholesterol within the individual plasma lipoproteins, were consistent with an increased influx into plasma of non-esterified cholesterol within VLDL, and an increased efflux of cholesterol from plasma within LDL.

Triiodothyronine accelerates maturation of bile acid metabolism in infant baboons

1995 ◽  
Vol 268 (5) ◽  
pp. E889-E896
Author(s):  
D. S. Lewis ◽  
E. M. Jackson ◽  
G. E. Mott
Keyword(s):  
Bile Acid ◽  
Acid Metabolism ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Pool Size ◽  
Bile Acid Metabolism ◽  
Low Density ◽  
Mrna Levels ◽  
Synthetic Rate ◽  
Preweaning Period

We tested the hypothesis that triiodothyronine (T3) treatment accelerates the early postnatal maturation of bile acid metabolism in the baboon. Infant baboons were implanted with 21-day-release pellets containing T3 (n = 12), a placebo pellet (n = 6), or no pellet (n = 13). T3 treatment increased plasma T3 concentrations from 3.0 to 5.0 nmol/l between birth and 15 wk of age. At 15 wk of age, bile acid pool sizes, fractional turnover rates (FTR), and synthetic rates were determined by an isotope-dilution method with 3H- and 14C-labeled cholic (CA) and chenodeoxycholic acid (CDCA). T3 treatment increased CA pool size by 47% and CA synthetic rate by 37% but did not significantly affect CDCA pool size or synthetic rate. Consequently CA-to-CDCA pool size ratio (0.77 vs. 0.42) and biliary CA-to-CDCA concentration ratio (0.88 vs. 0.46) were higher in the T3-treated infants than in combined placebo-treated and nontreated control infants. T3 treatment did not affect the bile acid glycine-to-taurine conjugate ratio, CA FTR, or CDCA pool size, FTR, and synthetic rate. T3 treatment lowered plasma high-density lipoprotein fraction 2 and 3 cholesterol concentrations by 22 and 40%, respectively. T3 treatment also increased hepatic low-density lipoprotein receptor mRNA levels but did not affect plasma low-density lipoprotein cholesterol concentrations. We conclude that modest elevation of plasma T3 during the preweaning period increases the CA-to-CDCA ratio at the end of the preweaning period to near adult values.

scholarly journals Impaired absorption of cholesterol and bile acids in patients with an ileoanal anastomosis

Gut ◽  
1997 ◽  
Vol 41 (6) ◽  
pp. 771-777 ◽  
Author(s):  
K Hakala ◽  
M Vuoristo ◽  
P Luukkonen ◽  
H J Järvinen ◽  
T A Miettinen
Keyword(s):  
Bile Acid ◽  
Bile Acids ◽  
Acid Metabolism ◽  
Saturation Index ◽  
Low Density Lipoprotein ◽  
Ileoanal Anastomosis ◽  
Density Lipoprotein ◽  
Cholesterol Absorption ◽  
Bile Acid Metabolism ◽  
Secondary Bile Acids

Background—No data exist on cholesterol absorption in patients with an ileoanal anastomosis (IAA).Aims—To study cholesterol absorption and its effects on cholesterol and bile acid metabolism in patients with an IAA.Patients and methods—Cholesterol absorption, and serum, biliary, and faecal lipids were studied in 24 patients with an IAA and 20 controls.Results—Fractional cholesterol absorption was significantly lower in the patients (36% versus 47% in controls). Surprisingly, the calculated intestinal influx of endogenous cholesterol was reduced so that the absolute absorption of cholesterol was decreased; elimination of cholesterol as faecal neutral steroids remained normal. Thus, the slightly increased cholesterol synthesis was mainly due to increased faecal bile acid excretion, which, in turn, was associated with reduced absorption and biliary secretion of bile acids. Serum total and low density lipoprotein (LDL) cholesterol and LDL triglycerides were lower in the patients. Molar percentage and saturation index of biliary cholesterol were slightly higher in patients with an IAA. Proportions of secondary bile acids in bile and faeces were diminished, and faecal unidentified bile acids were higher in patients.Conclusions—Cholesterol absorption is significantly impaired in patients with an IAA, and is closely related to changes in serum and biliary lipids observed in these patients.

Bile Acids: The Good, the Bad, and the Ugly

Physiology ◽  
1999 ◽  
Vol 14 (1) ◽  
pp. 24-29 ◽  
Author(s):  
Alan F. Hofmann
Keyword(s):  
Bile Acids ◽  
Enterohepatic Circulation ◽  
Cholesterol Metabolism ◽  
Plasma Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Absorption ◽  
Bile Acid Metabolism ◽  
Cholesterol Levels ◽  
Density Lipoprotein Receptor

Bile acids, amphipathic end products of cholesterol metabolism, are “good” in the infant because they enhance lipid absorption and thereby promote growth. Bile acids also induce bile flow and biliary lipid secretion. The enterohepatic circulation of bile acids is “bad” in the adult because it downregulates hepatocyte low-density lipoprotein receptor activity and thereby elevates plasma cholesterol levels. Defects in bile acid metabolism such as impaired biosynthesis or transport are “ugly” because they cause morbidity and death. New approaches for treating these defects are being developed.

scholarly journals Inulin Supplementation Disturbs Hepatic Cholesterol and Bile Acid Metabolism Independent from Housing Temperature

Nutrients ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3200
Author(s):  
Mira J. Pauly ◽  
Julia K. Rohde ◽  
Clara John ◽  
Ioannis Evangelakos ◽  
Anja Christina Koop ◽  
...  
Keyword(s):  
Bile Acid ◽  
Acid Metabolism ◽  
Plasma Cholesterol ◽  
Cold Treatment ◽  
Short Chain Fatty Acids ◽  
Liver Cholesterol ◽  
Bile Acid Metabolism ◽  
Short Term ◽  
Hepatic Bile ◽  
Brown Adipose

Dietary fibers are fermented by gut bacteria into the major short chain fatty acids (SCFAs) acetate, propionate, and butyrate. Generally, fiber-rich diets are believed to improve metabolic health. However, recent studies suggest that long-term supplementation with fibers causes changes in hepatic bile acid metabolism, hepatocyte damage, and hepatocellular cancer in dysbiotic mice. Alterations in hepatic bile acid metabolism have also been reported after cold-induced activation of brown adipose tissue. Here, we aim to investigate the effects of short-term dietary inulin supplementation on liver cholesterol and bile acid metabolism in control and cold housed specific pathogen free wild type (WT) mice. We found that short-term inulin feeding lowered plasma cholesterol levels and provoked cholestasis and mild liver damage in WT mice. Of note, inulin feeding caused marked perturbations in bile acid metabolism, which were aggravated by cold treatment. Our studies indicate that even relatively short periods of inulin consumption in mice with an intact gut microbiome have detrimental effects on liver metabolism and function.

scholarly journals Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles

2021 ◽  
Vol 11 (1) ◽  
pp. 4
Author(s):  
Boyan Zhang ◽  
Folkert Kuipers ◽  
Jan Freark de de Boer ◽  
Jan Albert Kuivenhoven
Keyword(s):  
Bile Acid ◽  
Bile Acids ◽  
Acid Metabolism ◽  
Ldl Cholesterol ◽  
Farnesoid X Receptor ◽  
New Drugs ◽  
Bile Acid Metabolism ◽  
Atherosclerotic Cardiovascular Disease ◽  
Faecal Excretion ◽  
Alcoholic Fatty Liver

New drugs targeting bile acid metabolism are currently being evaluated in clinical studies for their potential to treat cholestatic liver diseases, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Changes in bile acid metabolism, however, translate into an alteration of plasma cholesterol and triglyceride concentrations, which may also affect cardiovascular outcomes in such patients. This review attempts to gain insight into this matter and improve our understanding of the interactions between bile acid and lipid metabolism. Bile acid sequestrants (BAS), which bind bile acids in the intestine and promote their faecal excretion, have long been used in the clinic to reduce LDL cholesterol and, thereby, atherosclerotic cardiovascular disease (ASCVD) risk. However, BAS modestly but consistently increase plasma triglycerides, which is considered a causal risk factor for ASCVD. Like BAS, inhibitors of the apical sodium-dependent bile acid transporter (ASBTi’s) reduce intestinal bile acid absorption. ASBTi’s show effects that are quite similar to those obtained with BAS, which is anticipated when considering that accelerated faecal loss of bile acids is compensated by an increased hepatic synthesis of bile acids from cholesterol. Oppositely, treatment with farnesoid X receptor agonists, resulting in inhibition of bile acid synthesis, appears to be associated with increased LDL cholesterol. In conclusion, the increasing efforts to employ drugs that intervene in bile acid metabolism and signalling pathways for the treatment of metabolic diseases such as NAFLD warrants reinforcing interactions between the bile acid and lipid and lipoprotein research fields. This review may be considered as the first step in this process.

scholarly journals Myostatin Knockout Regulates Bile Acid Metabolism by Promoting Bile Acid Synthesis in Cattle

Animals ◽  
2022 ◽  
Vol 12 (2) ◽  
pp. 205
Author(s):  
Di Wu ◽  
Mingjuan Gu ◽  
Zhuying Wei ◽  
Chunling Bai ◽  
Guanghua Su ◽  
...  
Keyword(s):  
Bile Acid ◽  
Bile Acids ◽  
Acid Metabolism ◽  
Density Lipoprotein ◽  
Acid Synthesis ◽  
Bile Acid Synthesis ◽  
Negative Regulator ◽  
Bile Acid Metabolism ◽  
Metabolomic Analysis ◽  
Metabolomics Data

Myostatin (MSTN) is a major negative regulator of skeletal muscle mass and causes a variety of metabolic changes. However, the effect of MSTN knockout on bile acid metabolism has rarely been reported. In this study, the physiological and biochemical alterations of serum in MSTN+/− and wild type (WT) cattle were investigated. There were no significant changes in liver and kidney biochemical indexes. However, compared with the WT cattle, lactate dehydrogenase, total bile acid (TBA), cholesterol, and high-density lipoprotein (HDL) in the MSTN+/− cattle were significantly increased, and glucose, low-density lipoprotein (LDL), and triglycerides (TG) were significantly decreased, indicating that MSTN knockout affected glucose and lipid metabolism and total bile acids content. Targeted metabolomic analysis of the bile acids and their derivatives was performed on serum samples and found that bile acids were significantly increased in the MSTN+/− cattle compared with the WT cattle. As the only bile acid synthesis organ in the body, we performed metabolomic analysis on the liver to study the effect of MSTN knockout on hepatic metabolism. Metabolic pathway enrichment analysis of differential metabolites showed significant enrichment of the primary bile acid biosynthesis and bile secretion pathway in the MSTN+/− cattle. Targeted metabolomics data further showed that MSTN knockout significantly increased bile acid content in the liver, which may have resulted from enhanced bile acid synthesis due to the expression of bile acid synthesis genes, cholesterol 7 alpha-hydroxylase (CYP7A1) and sterol 27-hydroxylase (CYP27A1), and upregulation in the liver of the MSTN+/− cattle. These results indicate that MSTN knockout does not adversely affect bovine fitness but regulates bile acid metabolism via enhanced bile acid synthesis. This further suggests a role of MSTN in regulating metabolism.

Dynamics of the enterohepatic circulation of bile acids in healthy humans

2021 ◽  
Author(s):  
Frans Stellaard ◽  
Dieter Lütjohann
Keyword(s):  
Bile Acid ◽  
Bile Acids ◽  
Acid Metabolism ◽  
Enterohepatic Circulation ◽  
Feedback Inhibition ◽  
Acid Synthesis ◽  
Bile Acid Synthesis ◽  
Farnesoid X Receptor ◽  
Bile Acid Metabolism ◽  
Healthy Humans

Regulation of bile acid metabolism is normally discussed as the regulation of bile acid synthesis, which serves to compensate for intestinal loss in order to maintain a constant pool size. After a meal, bile acids start cycling in the enterohepatic circulation. Farnesoid X receptor-dependent ileal and hepatic processes lead to negative feedback inhibition of bile acid synthesis. When the intestinal bile acid flux decreases, the inhibition of synthesis is released. The degree of inhibition of synthesis and the mechanism and degree of activation are still unknown. Moreover, in humans, a biphasic diurnal expression pattern of bile acid synthesis has been documented, indicating maximal synthesis around 3 pm and 9 pm. Quantitative data on the hourly synthesis schedule as compensation for intestinal loss are lacking. In this review, we describe the classical view on bile acid metabolism and present alternative concepts that are based on the overlooked feature that bile acids transit through the enterohepatic circulation very rapidly. A daily profile of the cycling and total bile acid pool sizes and potential controlled and uncontrolled mechanisms for synthesis are predicted. It remains to be elucidated by which mechanism clock genes interact with the Farnesoid X receptor-controlled regulation of bile acid synthesis. This mechanism could become an attractive target to enhance bile acid synthesis at night, when cholesterol synthesis is high, thus lowering serum LDL-cholesterol.

Abstract 402: Post-transcriptional Regulation of Bile Acid Metabolism by the RNA binding protein ZFP36L1

2017 ◽  
Vol 37 (suppl_1) ◽  
Author(s):  
Elizabeth Tarling ◽  
Joan Cheng ◽  
Angela Cheng ◽  
Pauline Morand ◽  
Bethan Clifford ◽  
...  
Keyword(s):  
Bile Acid ◽  
Bile Acids ◽  
Acid Metabolism ◽  
Rna Binding ◽  
Binding Protein ◽  
Plasma Cholesterol ◽  
Rna Binding Protein ◽  
Lipid Absorption ◽  
Bile Acid Metabolism ◽  
Mrna Levels

Bile acids are detergents and important signaling molecules that activate the nuclear receptor FXR to control key metabolic processes, including feedback mechanisms to maintain bile acid homeostasis. Activation of FXR decreases the mRNA levels of several bile acid synthetic genes, including the rate-limiting enzyme Cyp7a1 . Here we show that Cyp7a1 mRNA levels are very rapidly reduced following FXR activation, indicative of a post-transcriptional mechanism. We identify the RNA binding protein Zfp36l1 as an FXR target gene and show that hepatic overexpression of ZFP36L1 in mice decreases Cyp7a1 mRNA levels. In contrast, Zfp36l1 L -KO mice have increased levels of Cyp7a1 mRNA and biliary bile acids as well as reduced plasma cholesterol levels. Zfp36l1 L -KO mice fed a Western diet have reduced diet-induced obesity and steatosis, likely due to impaired lipid absorption, consistent with increased Cyp7a1 levels. Thus, the ZFP36L1-dependent regulation of bile acid metabolism is an important metabolic contributor of dyslipidemia, obesity and hepatosteatosis.

Sign in / Sign up

Export Citation Format

Share Document